NASDAQ:FATE Fate Therapeutics (FATE) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free FATE Stock Alerts $4.30 -0.24 (-5.29%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$4.17▼$4.6650-Day Range$4.54▼$8.3552-Week Range$1.63▼$8.83Volume2.27 million shsAverage Volume2.77 million shsMarket Capitalization$489.41 millionP/E RatioN/ADividend YieldN/APrice Target$6.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Fate Therapeutics alerts: Email Address Fate Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.08 Rating ScoreUpside/Downside56.4% Upside$6.73 Price TargetShort InterestBearish19.01% of Float Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.34Based on 10 Articles This WeekInsider TradingSelling Shares$9,245 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.94) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.15 out of 5 starsMedical Sector141st out of 909 stocksBiological Products, Except Diagnostic Industry15th out of 156 stocks 4.0 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 2 buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageFate Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.01% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 25.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fate Therapeutics is -0.70. Previous Next 1.9 News and Social Media Coverage News SentimentFate Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for FATE on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,245.00 in company stock.Percentage Held by InsidersOnly 5.04% of the stock of Fate Therapeutics is held by insiders.Percentage Held by Institutions97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to grow in the coming year, from ($1.94) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Fate Therapeutics Stock (NASDAQ:FATE)Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More FATE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FATE Stock News HeadlinesApril 24, 2024 | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Given "Neutral" Rating at WedbushApril 24, 2024 | americanbankingnews.comReviewing Immatics (NASDAQ:IMTX) & Fate Therapeutics (NASDAQ:FATE)April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 23, 2024 | nytimes.comOur Reporter on the Fate of a Gazan University ClassApril 22, 2024 | globenewswire.comFate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingApril 22, 2024 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by AnalystsApril 21, 2024 | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Stock Price Down 5.4%April 18, 2024 | msn.comFate Therapeutics files to sell 3.64M shares for holdersApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 10, 2024 | msn.comA promising target for new RNA therapeutics now accessibleApril 3, 2024 | yahoo.comTerminator: Edward Furlong Addresses John Connor’s Death In Dark FateApril 3, 2024 | uk.movies.yahoo.com‘It Was A Mixed Feeling’: Terminator’s Edward Furlong Opens Up About Shooting His Controversial John Connor Cameo In Dark FateApril 3, 2024 | finance.yahoo.comFate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | globenewswire.comFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)March 31, 2024 | nz.news.yahoo.comX Factor star Lucy Spraggan says Simon Cowell will walk her down the aisle at weddingMarch 31, 2024 | msn.comI visited Mother Mercy to learn more about their new Twist of Fate experience - and tried it out for myselfMarch 29, 2024 | markets.businessinsider.comCautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation ConcernsMarch 24, 2024 | benzinga.comFate Therapeutics Stock (NASDAQ:FATE), Quotes and News SummaryMarch 19, 2024 | markets.businessinsider.comEvaluating Fate Therapeutics: Insights From 5 Financial AnalystsMarch 19, 2024 | markets.businessinsider.comFate Therapeutics Prices $100 Mln Of Public Offering, Concurrent Private PlacementMarch 19, 2024 | msn.comFate Therapeutics announces pricing of $100M underwritten offering and concurrent private placementMarch 19, 2024 | globenewswire.comFate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private PlacementMarch 16, 2024 | finance.yahoo.comFATE Apr 2024 5.000 putMarch 16, 2024 | finance.yahoo.comFATE Aug 2024 5.000 putMarch 16, 2024 | finance.yahoo.comFATE Apr 2024 7.500 putMarch 14, 2024 | msn.comVindictus: Defying Fate is worth trying for free even if you never played the MMOMarch 7, 2024 | finance.yahoo.comFATE Mar 2024 10.000 putSee More Headlines Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/24/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees181Year FoundedN/APrice Target and Rating Average Stock Price Target$6.73 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+57.5%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,930,000.00 Net Margins-253.30% Pretax Margin-253.30% Return on Equity-38.17% Return on Assets-28.42% Debt Debt-to-Equity RatioN/A Current Ratio8.48 Quick Ratio8.48 Sales & Book Value Annual Sales$63.53 million Price / Sales7.65 Cash FlowN/A Price / Cash FlowN/A Book Value$3.74 per share Price / Book1.14Miscellaneous Outstanding Shares113,817,000Free Float108,081,000Market Cap$486.00 million OptionableOptionable Beta1.66 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. J. Scott Wolchko (Age 54)Founder, CEO, President & Director Comp: $645kMr. Edward J. Dulac III (Age 48)Chief Financial Officer Comp: $455kMs. Cindy R. Tahl J.D. (Age 51)General Counsel, Corporate Secretary & Compliance Officer Comp: $455kDr. Bahram Valamehr Ph.D. (Age 47)Chief Research & Development Officer Comp: $455kMr. Jim Beitel M.B.A.Senior Vice President of Corporate DevelopmentDr. Jerome Bressi Ph.D.Senior Vice President of Regulatory & QualityDr. Barbara HickingbottomSenior VP of Clinical DevelopmentMore ExecutivesKey CompetitorsAlectorNASDAQ:ALECExscientiaNASDAQ:EXAIValnevaNASDAQ:VALNC4 TherapeuticsNASDAQ:CCCCTaysha Gene TherapiesNASDAQ:TSHAView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 2,385,207 shares on 4/24/2024Ownership: 2.239%Simplicity Wealth LLCBought 11,016 shares on 4/24/2024Ownership: 0.010%Vestal Point Capital LPBought 1,290,000 shares on 2/14/2024Ownership: 1.308%Superstring Capital Management LPBought 847,823 shares on 2/14/2024Ownership: 0.860%Pennant Investors LPBought 146,100 shares on 2/14/2024Ownership: 0.148%View All Insider TransactionsView All Institutional Transactions FATE Stock Analysis - Frequently Asked Questions Should I buy or sell Fate Therapeutics stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 sell rating, 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. View FATE analyst ratings or view top-rated stocks. What is Fate Therapeutics' stock price target for 2024? 12 equities research analysts have issued 1 year price objectives for Fate Therapeutics' shares. Their FATE share price targets range from $5.00 to $10.00. On average, they predict the company's share price to reach $6.73 in the next twelve months. This suggests a possible upside of 56.4% from the stock's current price. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. How have FATE shares performed in 2024? Fate Therapeutics' stock was trading at $3.74 on January 1st, 2024. Since then, FATE stock has increased by 15.0% and is now trading at $4.30. View the best growth stocks for 2024 here. Are investors shorting Fate Therapeutics? Fate Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 16,490,000 shares, an increase of 25.3% from the March 15th total of 13,160,000 shares. Based on an average trading volume of 2,860,000 shares, the days-to-cover ratio is currently 5.8 days. Approximately 19.0% of the company's shares are short sold. View Fate Therapeutics' Short Interest. When is Fate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our FATE earnings forecast. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12. The biopharmaceutical company earned $1.68 million during the quarter, compared to analysts' expectations of $0.85 million. Fate Therapeutics had a negative net margin of 253.30% and a negative trailing twelve-month return on equity of 38.17%. During the same period in the prior year, the firm posted ($0.58) EPS. What ETFs hold Fate Therapeutics' stock? ETFs with the largest weight of Fate Therapeutics (NASDAQ:FATE) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Tema Oncology ETF (CANC). What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (2.24%) and Simplicity Wealth LLC (0.01%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FATE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe Greatest Bull Market in Crypto History…Weiss RatingsNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
